208 related articles for article (PubMed ID: 36345697)
21. A split face study to document the safety and efficacy of clearance of melasma with a 5 ns q switched Nd YAG laser versus a 50 ns q switched Nd YAG laser.
Alsaad SM; Ross EV; Mishra V; Miller L
Lasers Surg Med; 2014 Dec; 46(10):736-40. PubMed ID: 25411141
[TBL] [Abstract][Full Text] [Related]
22. Split-face comparison of hydroquinone 4% plus nitrogen plasma vs. hydroquinone 4% alone in the treatment of melasma.
Yousefi M; Hadian K; Babossalam S; Diab R; Akhlaghi M; Aghighi M; Abdollahimajd F; Shokri B
Lasers Med Sci; 2023 Apr; 38(1):113. PubMed ID: 37103690
[TBL] [Abstract][Full Text] [Related]
23. Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma.
Shihab N; Prihartono J; Tovar-Garza A; Agustin T; Legiawati L; Pandya AG
Australas J Dermatol; 2020 Aug; 61(3):237-242. PubMed ID: 32109318
[TBL] [Abstract][Full Text] [Related]
24. A Randomized, Double-Blind, Split-Face Study of Topical Silymarin vs 2% Hydroquinone Cream in Melasmas.
Wattanakrai P; Nimmannitya K
J Drugs Dermatol; 2022 Dec; 21(12):1304-1310. PubMed ID: 36468967
[TBL] [Abstract][Full Text] [Related]
25. A prospective, split-face study comparing 1,064-nm picosecond Nd:YAG laser toning with 1,064-nm Q-switched Nd:YAG laser toning in the treatment of melasma.
Hong JK; Shin SH; Park SJ; Seo SJ; Park KY
J Dermatolog Treat; 2022 Aug; 33(5):2547-2553. PubMed ID: 35067157
[TBL] [Abstract][Full Text] [Related]
26. Fractional 1064 nm Picosecond Laser in Treatment of Melasma and Skin Rejuvenation in Asians, A Prospective Study.
Wong CSM; Chan MWM; Shek SYN; Yeung CK; Chan HHL
Lasers Surg Med; 2021 Oct; 53(8):1032-1042. PubMed ID: 33544930
[TBL] [Abstract][Full Text] [Related]
27. Prospective randomized controlled trial comparing treatment efficacy and tolerance of picosecond alexandrite laser with a diffractive lens array and triple combination cream in female asian patients with melasma.
Wang YJ; Lin ET; Chen YT; Chiu PC; Lin BS; Chiang HM; Huang YH; Wang KY; Lin HY; Chang TM; Chang CC
J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):624-632. PubMed ID: 31494973
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomised, double-blinded trial.
Nguyen J; Remyn L; Chung IY; Honigman A; Gourani-Tehrani S; Wutami I; Wong C; Paul E; Rodrigues M
Australas J Dermatol; 2021 Feb; 62(1):e41-e46. PubMed ID: 32981068
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of tranexamic acid 5% cream vs hydroquinone 4% cream in treating melasma: A split-face comparative clinical, histopathological, and antera 3D camera study.
El-Husseiny R; Rakha N; Sallam M
Dermatol Ther; 2020 Nov; 33(6):e14240. PubMed ID: 32856757
[TBL] [Abstract][Full Text] [Related]
30. Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial.
Saki N; Darayesh M; Heiran A
J Dermatolog Treat; 2018 Jun; 29(4):405-410. PubMed ID: 29027510
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the efficacy and safety of combinations of hydroquinone, glycolic acid, and hyaluronic acid in the treatment of melasma.
Ibrahim ZA; Gheida SF; El Maghraby GM; Farag ZE
J Cosmet Dermatol; 2015 Jun; 14(2):113-23. PubMed ID: 25847063
[TBL] [Abstract][Full Text] [Related]
32. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
Chan R; Park KC; Lee MH; Lee ES; Chang SE; Leow YH; Tay YK; Legarda-Montinola F; Tsai RY; Tsai TH; Shek S; Kerrouche N; Thomas G; Verallo-Rowell V
Br J Dermatol; 2008 Sep; 159(3):697-703. PubMed ID: 18616780
[TBL] [Abstract][Full Text] [Related]
33. Fractional erbium-doped yttrium aluminum garnet laser-assisted drug delivery of hydroquinone in the treatment of melasma.
Badawi AM; Osman MA
Clin Cosmet Investig Dermatol; 2018; 11():13-20. PubMed ID: 29379308
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the efficacy of cysteamine 5% cream and hydroquinone 4%/ascorbic acid 3% combination cream in the treatment of epidermal melasma.
Sepaskhah M; Karimi F; Bagheri Z; Kasraee B
J Cosmet Dermatol; 2022 Jul; 21(7):2871-2878. PubMed ID: 35510765
[TBL] [Abstract][Full Text] [Related]
35. Melasma treatment with a 1064 nm, picosecond-domain laser with a fractionated multibeam lens array.
Bernstein EF; Basilavecchio LD; Wang J
Lasers Surg Med; 2023 Nov; 55(9):801-808. PubMed ID: 37668307
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial.
Lima PB; Dias JAF; Cassiano DP; Esposito ACC; Miot LDB; Bagatin E; Miot HA
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1881-1887. PubMed ID: 33988887
[TBL] [Abstract][Full Text] [Related]
37. A randomized, split-face clinical trial of low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser versus low-fluence Q-switched alexandrite laser (755 nm) for the treatment of facial melasma.
Fabi SG; Friedmann DP; Niwa Massaki AB; Goldman MP
Lasers Surg Med; 2014 Sep; 46(7):531-7. PubMed ID: 24895301
[TBL] [Abstract][Full Text] [Related]
38. Low-fluence Q-switched Nd: YAG 1064-nm laser and intense pulsed light for the treatment of melasma.
Vachiramon V; Sirithanabadeekul P; Sahawatwong S
J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1339-46. PubMed ID: 25413592
[TBL] [Abstract][Full Text] [Related]
39. The efficacy in treatment of facial melasma with thulium 1927-nm fractional laser-assisted topical tranexamic acid delivery: a split-face, double-blind, randomized controlled pilot study.
Wanitphakdeedecha R; Sy-Alvarado F; Patthamalai P; Techapichetvanich T; Eimpunth S; Manuskiatti W
Lasers Med Sci; 2020 Dec; 35(9):2015-2021. PubMed ID: 32506227
[TBL] [Abstract][Full Text] [Related]
40. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
Kaufman BP; Alexis AF
J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
